Exhibit 99.1

FORM 51-102F3

MATERIAL CHANGE REPORT

ITEM 1.	Name and Address of Company
	Aurinia Pharmaceuticals Inc. (the “Company”)
	1203 – 4464 Markham Street
	Victoria, BC V8Z 7X8
ITEM 2.	Date of Material Change
	February 6, 2017
ITEM 3.	News Release
	A news release relating to the material change described herein was disseminated on February 6, 2017 via Business Wire.
ITEM 4.	Summary of Material Change
	The Company announced the resignation of Charles Rowland as Chief Executive Officer and director of the Company and the appointment of Dr. Richard M. Glickman, the Company's founder and Chairman of the Board, as the Company’s Chairman and Chief Executive Officer, effective February 6, 2017.
ITEM 5.	Full Description of Material Change
	The Company announced the resignation of Charles Rowland as Chief Executive Officer and director of the Company and the appointment of Dr. Richard M. Glickman, the Company's founder and Chairman of the Board, as the Company’s Chairman and Chief Executive Officer, effective February 6, 2017.
ITEM 5.2.	Disclosure of Restructuring Transactions
	Not applicable.
ITEM 6.	Reliance on Subsection 7.1(2) of National Instrument 51-102
	Not applicable.
ITEM 7.	Omitted Information
	There are no significant facts required to be disclosed herein which have been omitted.
ITEM 8.	Executive Officer
	For further information, please contact:
	Michael R. Martin, Chief Operating Officer
	250-415-9713
	mmartin@auriniapharma.com
ITEM 9.	Date of Report
	February 16, 2017